Who Paid My Doc
Lane Miller
College Station, TX Medical Doctor
NPI 1316986631 CMS profile 14175
1721 Birmingham Dr, Ste 204, College Station, TX 77845
General payments
$11,114
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$26,073
Through program year 2025, Lane Miller of College Station, TX is reported in the CMS Open Payments database as having received $11,114 across 541 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $26,073 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,334 | 49 | |
| 2024 | General | $1,830 | 81 | |
| 2023 | General | $1,829 | 83 | |
| 2022 | General | $1,645 | 98 | |
| 2021 | General | $1,849 | 85 | |
| 2020 | General | $969 | 29 | |
| 2019 | General | $1,658 | 116 |
Beside peers
- Lane Miller
- Texas median
- Middle half of Texas
- National median
In program year 2025, general payments to Lane Miller were reported at $1,334. Among 86,592 Texas profiles paid that year, the median was $188 and the middle half received between $55 and $669.
Show as a table
| Year | Lane Miller | Texas median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,658 | $191 | $56–$744 | $163 |
| 2020 | $969 | $125 | $38–$452 | $114 |
| 2021 | $1,849 | $150 | $43–$543 | $132 |
| 2022 | $1,645 | $169 | $50–$606 | $149 |
| 2023 | $1,829 | $183 | $53–$639 | $160 |
| 2024 | $1,830 | $188 | $55–$666 | $164 |
| 2025 | $1,334 | $188 | $55–$669 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 65 drugsPart D claims
9,619
Drug cost
$2,037,721
Branded share of claims
36%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 1,066 | $874,694 | |
| Multaq Dronedarone Hcl | Brand | 236 | $247,044 | |
| Entresto Sacubitril/Valsartan | Brand | 239 | $212,356 | |
| Camzyos Mavacamten | Brand | 14 | $118,919 | |
| Repatha Sureclick Evolocumab | Brand | 180 | $115,103 | |
| Xarelto Rivaroxaban | Brand | 93 | $112,746 | |
| Brilinta Ticagrelor | Brand | 172 | $99,754 | |
| Jardiance Empagliflozin | Brand | 83 | $65,503 | |
| Farxiga Dapagliflozin Propanediol | Brand | 36 | $28,670 | |
| Vascepa Icosapent Ethyl | Brand | 47 | $24,385 |
The 10 drugs with the highest cost, of 65 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 107 billing codesPaid by Medicare
$795,723
Medicare patients
996
Services billed
8,238
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 51% | |
| Arthritis | 47% | |
| Atrial fibrillation | 35% | |
| Diabetes | 33% | |
| Chronic kidney disease | 29% | |
| Heart failure | 28% | |
| Depression | 21% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, regadenoson, 0.1 mg J2785 | Office | 213 | 849 | $4,505 |
| Injection, aminophyllin, up to 250 mg J0280 | Office | 43 | 43 | $165 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 16 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| CAMZYOS |
|
$117 | 14 | — |
| LEQVIO |
|
$97 | — | — |
| Repatha |
|
$74 | 180 | — |
| Arcalyst |
|
$64 | — | — |
| INJECTAFER |
|
$40 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 16 in the dashboard with a free accountRecords
541 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.